Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 9/20 | 0.54 |
| ▸ | TAS1R1 | Q7RTX1 | 9/20 | 0.54 |
| ▸ | TAS1R2 | Q8TE23 | 9/20 | 0.54 |
| ▸ | RECQL | P46063 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | DHODH | Q02127 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | CFD | P00746 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6315372 | 0.95 | TAS1R3 (0.46) | TAS1R3TAS1R1TAS1R2RECQLTSHR | |
| SCHEMBL6323933 | 0.88 | RECQL (0.47) | TAS1R3TAS1R1TAS1R2RECQLTSHR | |
| SCHEMBL6322801 | 0.87 | TAS1R3 (0.55) | TAS1R3TAS1R1TAS1R2RECQLTSHR | |
| SCHEMBL6317860 | 0.83 | ALDH1A1 (0.60) | TAS1R3TAS1R1TAS1R2RECQLTSHR | |
| SCHEMBL6318467 | 0.83 | NPC1 (0.59) | TSHRALDH1A1SMN1; SMN2 | |
| SCHEMBL6317385 | 0.83 | NPC1 (0.61) | TSHRALDH1A1SMN1; SMN2 | |
| SCHEMBL6317913 | 0.83 | MLLT3 (0.41) | TAS1R3TAS1R1TAS1R2RECQLTSHR | |
| SCHEMBL6321193 | 0.82 | NPC1 (0.62) | TSHRALDH1A1SMN1; SMN2 | |
| SCHEMBL6316754 | 0.82 | NPC1 (0.62) | TSHRALDH1A1SMN1; SMN2 | |
| SCHEMBL6323374 | 0.81 | CA1 (0.49) | TAS1R3TAS1R1TAS1R2RECQLTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050059657-A1 | Aminoisoxazole derivatives active as kinase inhibitors | PFIZER ITALIA S.R.L. (IT) | 2005-03-17 | — | — | US | claimed |
| EP-1435948-A1 | AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | Pharmacia Italia S.p.A. (IT) | 2004-07-14 | — | — | EP | claimed |
| WO-2003013517-A1 | AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | PHARMACIA ITALIA S.P.A. (IT) | 2003-02-20 | — | — | WO | claimed |
| US-20050059657-A1 | Aminoisoxazole derivatives active as kinase inhibitors | PFIZER ITALIA S.R.L. (IT) | 2005-03-17 | — | — | US | disclosed |
| EP-1435948-A1 | AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | Pharmacia Italia S.p.A. (IT) | 2004-07-14 | — | — | EP | disclosed |
| WO-2003013517-A1 | AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | PHARMACIA ITALIA S.P.A. (IT) | 2003-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050059657-A1 | Aminoisoxazole derivatives active as kinase inhibitors | MAP3K9, MAP3K19, MAP4K2 | TAS1R3 4289/4885TAS1R1 4258/4885TAS1R2 4472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.